Table 3.

Cross-sectional association between CMV seropositivity, inflammation score and cognitive impairment among cancer survivors diagnosed within three years of biomarker measurement and those diagnosed with cancer ≥ 3 years prior to biomarker measurement

Predictors	Cancer diagnosed within three years of measurement of inflammation score/CMV status n = 313 (21.5%)	Cancer diagnosed ≥ three years of measurement of inflammation score/CMV status n = 1141 (78.5%)
	OR (95% CI)	OR (95% CI)
CMV seropositivity
CMV seropositive	2.3 (1.1,5.2)	1.2 (0.7,1.9)
CMV seronegative	Ref	Ref
Inflammation score
High	6.4 (2.5,16.6)	1.3 (0.6,2.6)
Low	Ref	Ref
CMV seropositivity and inflammation
CMV seropositive and high inflammation score	18.5 (6.1,56.1)	1.78 (0.6,5.4)
CMV seropositive and low inflammation score	2.6 (1.0,6.9)	1.2 (0.7,2.0)
CMV seronegative and high inflammation score	6.9 (1.3,38.1)	1.1 (0.2,5.1)
CMV seronegative and low inflammation score	Ref	Ref

The models were adjusted for age, sex, race/ethnicity, years of education, comorbidity index and survey design parameters (strata and cluster for sampling error and participant sample weights for the 2016 HRS Venous Blood Study)

CMV Cytomegalovirus